Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Acurx Pharmaceuticals Inc ACXP

Healthcare Biotechnology
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a... see more

Current News (NDAQ:ACXP)

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

PR Newswire November 18, 2025

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

PR Newswire November 12, 2025

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

PR Newswire November 10, 2025

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

PR Newswire October 28, 2025

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

PR Newswire October 27, 2025

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

PR Newswire October 9, 2025

Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

PR Newswire September 30, 2025

Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

PR Newswire September 3, 2025

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

PR Newswire August 12, 2025
View More News ››

Opinion & Analysis (NDAQ:ACXP)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ACXP)

Using technical analysis for this stock.

It is signalling a big upswing in share price today,so good luck to all of you guys out there
coolfooldumbguy - October 8, 2025

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP): A Promising Antib

http://beyondspx.com/2024/08/02/acurx-pharmaceuticals-inc-nasdaqacxp-a-promising-antibiotic-candidate-targeting-a-billion-dollar-market/
MikeTester - August 3, 2024

Ibezapolstat Takes Center Stage

https://www.marketwatch.com/press-release/acurx-pharmaceuticals-ibezapolstat-takes-center-stage-after-summit-therapeutics-misses-phase-3...
mattusvi - January 4, 2022
View more Bullboard ››

Forsys Metals Corp

Forsys Metals Corp

Forsys Metals Corp. together with its subsidiaries, engages in the acquisition, exploration, and development of uranium ...
View More »

Podcasts